Drake & Associates’s AbbVie ABBV Stock Holding History

Drake & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.03M	Buy	8,068 +203	+3%	+$43.7K	0.34%	23
2026 Q1	$1.71M	Sell	7,865 -41	-0.5%	-$9.1K	0.33%	25
2025 Q4	$1.81M	Sell	7,906 -98	-1%	-$22.3K	0.36%	34
2025 Q3	$1.73M	Buy	8,004 +145	+2%	+$29.5K	0.36%	44
2025 Q2	$1.46M	Buy	7,859 +48	+0.6%	+$8.92K	0.36%	40
2025 Q1	$1.64M	Sell	7,811 -14	-0.2%	-$2.72K	0.46%	32
2024 Q4	$1.49M	Buy	7,825 +513	+7%	+$94.3K	0.42%	27
2024 Q3	$1.44M	Buy	7,312 +300	+4%	+$56K	0.47%	20
2024 Q2	$1.2M	Sell	7,012 -185	-3%	-$30.6K	0.43%	21
2024 Q1	$1.31M	Hold	7,197	–	–	0.48%	21
2023 Q4	$1.12M	Hold	7,197	–	–	0.46%	21
2023 Q3	$1.07M	Sell	7,197 -298	-4%	-$43.7K	0.49%	21
2023 Q2	$1.01M	Buy	7,495 +23	+0.3%	+$3.37K	0.45%	22
2023 Q1	$1.19M	Sell	7,472 -43	-0.6%	-$6.57K	0.58%	18
2022 Q4	$1.21M	Buy	+7,515	New	+$1.15M	0.64%	18

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Drake & Associates's ABBV Position: Q2 2026 in Review

Drake & Associates increased its AbbVie (ABBV) stake by 2.6% in Q2 2026, buying an estimated $43.7K and bringing the position to 8,068 shares worth $2.03M. The position accounts for 0.34% of the portfolio, ranked #23.

Drake & Associates first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,187 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Drake & Associates held 8,068 shares of AbbVie worth $2.03M as of Q2 2026.
Drake & Associates bought 203 AbbVie shares in Q2 2026, an estimated $43.7K.
AbbVie made up 0.34% of Drake & Associates's portfolio in Q2 2026, its #23 holding.
Drake & Associates first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
4,187 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Drake & Associates's 13F filing for Q2 2026, filed 10 Aug 2026.